LPCAT2 and Alzheimer disease: Collectively, these findings identify LPCAT2 as a key molecular link between altered pain processing and AD progression, highlighting its potential as both a therapeutic target for genotype‐ and sex‐specific subpopulations and a prognostic biomarker for MCI‐to‐AD conversion.